Diabetes · Lakeland, FL
Diabetes studies in Lakeland, FL
6 recruiting studies have a site in Lakeland.
6 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2/Phase 3
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
AbbVie
- Location
- Lakeland, FL + 36 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Boehringer Ingelheim
- Location
- Lakeland, FL + 199 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
Boehringer Ingelheim
- Location
- Lakeland, FL + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
Boehringer Ingelheim
- Location
- Lakeland, FL + 56 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and…
Novo Nordisk A/S
- Location
- Lakeland, FL + 55 other US sites
- Eligibility basics
- Ages 45+
- RecruitingPhase 2
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
Sun Pharmaceutical Industries Limited
- Location
- Lakeland, FL + 8 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Studies commonly set an HbA1c range, a diagnosis duration and a list of allowed or excluded medications. Some also recruit people without diabetes as a comparison group.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.